Market Closed -
Other stock markets
|
After market 08:50:00 pm | |||
274.6 CHF | +0.81% | 273.3 | -0.47% |
08:42am | Roche: WHO prequalification for HPV testing | CF |
07:25am | Roche Receives Additional Prequalification Designations for HPV Test | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Sales forecast by analysts have been recently revised upwards.
Weaknesses
- The company's enterprise value to sales, at 3.52 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.05% | 225B | - | ||
+55.05% | 811B | C+ | ||
+43.62% | 640B | B | ||
-7.14% | 353B | C+ | ||
+17.85% | 333B | B- | ||
+8.92% | 302B | C+ | ||
+16.30% | 246B | B+ | ||
+12.47% | 218B | B- | ||
+8.57% | 168B | C+ | ||
-3.58% | 155B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ROG Stock
- 0QQ6 Stock
- Ratings Roche Holding AG